Peer-Reviewed Journal Details
Mandatory Fields
Paruch, K.,Dwyer, M. P.,Alvarez, C.,Brown, C.,Chan, T. Y.,Doll, R. J.,Keertikar, K.,Knutson, C.,McKittrick, B.,Rivera, J.,Rossman, R.,Tucker, G.,Fischmann, T. O.,Hruza, A.,Madison, V.,Nomeir, A. A.,Wang, Y.,Lees, E.,Parry, D.,Sgambellone, N.,Seghezzi, W.,Schultz, L.,Shanahan, F.,Wiswell, D.,Xu, X.,Zhou, Q.,James, R. A.,Paradkar, V. M.,Park, H.,Rokosz, L. R.,Stauffer, T. M.,Guzi, T. J.
2007
November
Bioorg Med Chem Lettbioorg Med Chem Lett
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
Validated
()
Optional Fields
17
2222
6220
3
Properly substituted pyrazolo[1,5-a]pyrimidines are potent and selective CDK2 inhibitors. Compound 15j is orally available and showed efficacy in a mouse A2780 xenograft model.Properly substituted pyrazolo[1,5-a]pyrimidines are potent and selective CDK2 inhibitors. Compound 15j is orally available and showed efficacy in a mouse A2780 xenograft model.
0960-894X (Print) 0960-89
Grant Details